Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock

Critical Care Medicine

Volumn 42, Issue 2, 2014, Pages 281-288

  Van Diepen, Sean ^a   Reynolds, Harmony R ^b   Stebbins, Amanda ^c   Lopes, Renato D ^c   Džavík, Vladimír ^d   Ruzyllo, Witold ^e   Geppert, Alexander ^f   Widimsky, Petr ^g   Ohman, E Magnus ^c   Parrillo, Joseph E ^h   Dauerman, Harold L ⁱ   Baran, David A ^j   Hochman, Judith S ^b   Alexander, John H ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e INSTITUTE OF CARDIOLOGY   (Poland)

^f WILHELMINEN HOSPITAL   (Austria)

^g CHARLES UNIVERSITY   (Czech Republic)

^h Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

ⁱ UNIVERSITY OF VERMONT   (United States)

^j NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

more..

Author keywords

Blockers; Aldosterone Antagonists; Angiotensin II Receptor Blockers; Angiotensinconverting Enzyme Inhibitors; Cardiogenic Shock; Myocardial Infarction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MINERALOCORTICOID ANTAGONIST; N(G)-MONOMETHYLARGININE ACETATE;

AGED; ANALOGS AND DERIVATIVES; CARDIOGENIC SHOCK; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; HEART FAILURE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TIME; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ARGININE; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENIN-ANGIOTENSIN SYSTEM; SHOCK, CARDIOGENIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84895075027     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31829f6242     Document Type: Article

References (29)

1. Jeger RV, Radovanovic D, Hunziker PR, et al; AMIS Plus Registry Investigators: Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med 2008; 149:618-626
2. Goldberg RJ, Spencer FA, Gore JM, et al: Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: A population-based perspective. Circulation 2009; 119:1211-1219
3. Abdel-Qadir HM, Ivanov J, Austin PC, et al: Temporal trends in cardiogenic shock treatment and outcomes among Ontario patients with myocardial infarction between 1992 and 2008. Circ Cardiovasc Qual Outcomes 2011; 4:440-447
4. Fox KA, Anderson FA Jr, Dabbous OH, et al; GRACE investigators: Intervention in acute coronary syndromes: Do patients undergo intervention on the basis of their risk characteristics The Global Registry of Acute Coronary Events (GRACE). Heart 2007; 93:177-182
5. Hochman JS, Sleeper LA, Webb JG, et al: Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999; 341:625-634
6. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001; 357:1385-1390
7. Freemantle N, Cleland J, Young P, et al: Beta blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999; 318:1730-1737
8. Pfeffer MA, Braunwald E, Moyé LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669-677
9. Køber L, Torp-Pedersen C, Carlsen JE, et al: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333:1670-1676
10. Pfeffer MA, McMurray JJ, Velazquez EJ, et al; Valsartan in Acute Myocardial Infarction Trial Investigators: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906
11. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321
12. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289:2560-2572
13. Rabi DM, Daskalopoulou SS, Padwal RS, et al; Canadian Hypertension Education Program: The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: Blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2011; 27:415-433.e1
14. Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association; Antman EM, Hand M, Armstrong PW, et al: 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51:210-247
15. Antman EM, Anbe DT, Armstrong PW, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction): ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588-636
16. The Triumph Investigators: Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock. JAMA 2007; 297:1657-1666
17. Metra M, Nodari S, DAloia A, et al: Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: A randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40:1248-1258
18. Shakar SF, Abraham WT, Gilbert EM, et al: Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998; 31:1336-1340
19. Hollenberg SM, Kavinsky CJ, Parrillo JE: Cardiogenic shock. Ann Intern Med 1999; 131:47-59
20. Hasdai D, Topol EJ, Califf RM, et al: Cardiogenic shock complicating acute coronary syndromes. Lancet 2000; 356:749-756
21. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007
22. European Society of Cardiology: Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of). Available at: Http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/ acs-st-segment-elevation.aspx. Accessed September 21, 2012
23. Eagle KA, Montoye CK, Riba AL, et al; American College of Cardiologys Guidelines Applied in Practice (GAP) Projects in Michigan; American College of Cardiology Foundation (Bethesda, Maryland) Guidelines Applied in Practice Steering committee: Guideline-based standardized care is associated with substantially lower mortality in medicare patients with acute myocardial infarction: The American College of Cardiologys Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol 2005; 46:1242-1248
24. Rasmussen JN, Chong A, Alter DA: Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297:177-186
25. Licker M, Neidhart P, Lustenberger S, et al: Long-term angiotensinconverting enzyme inhibitor treatment attenuates adrenergic responsiveness without altering hemodynamic control in patients undergoing cardiac surgery. Anesthesiology 1996; 84:789-800
26. Haber HL, Simek CL, Gimple LW, et al: Why do patients with congestive heart failure tolerate the initiation of beta-blocker therapy Circulation 1993; 88:1610-1619
27. Chen ZM, Pan HC, Chen YP, et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group: Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005; 366:1622-1632
28. Yan AT, Yan RT, Tan M, et al; Canadian ACS Registries Investigators: Optimal medical therapy at discharge in patients with acute coronary syndromes: Temporal changes, characteristics, and 1-year outcome. Am Heart J 2007; 154:1108-1115
29. Wang TY, Xiao L, Alexander KP, et al: Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation 2008; 118:2139-2145